IS6634A - Aðferð til að búa til sildenafíl - Google Patents

Aðferð til að búa til sildenafíl

Info

Publication number
IS6634A
IS6634A IS6634A IS6634A IS6634A IS 6634 A IS6634 A IS 6634A IS 6634 A IS6634 A IS 6634A IS 6634 A IS6634 A IS 6634A IS 6634 A IS6634 A IS 6634A
Authority
IS
Iceland
Prior art keywords
sildenafil
making
making sildenafil
Prior art date
Application number
IS6634A
Other languages
English (en)
Other versions
IS1923B (is
Inventor
James Dunn Peter
Shaw Wood Albert
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6634(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of IS6634A publication Critical patent/IS6634A/is
Publication of IS1923B publication Critical patent/IS1923B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
IS6634A 1996-06-14 2002-11-25 Aðferð til að búa til sildenafíl IS1923B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612514.1A GB9612514D0 (en) 1996-06-14 1996-06-14 Novel process

Publications (2)

Publication Number Publication Date
IS6634A true IS6634A (is) 2002-11-25
IS1923B IS1923B (is) 2004-03-15

Family

ID=10795332

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4503A IS1922B (is) 1996-06-14 1997-06-10 Aðferð til að búa til sildenafíl
IS6634A IS1923B (is) 1996-06-14 2002-11-25 Aðferð til að búa til sildenafíl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4503A IS1922B (is) 1996-06-14 1997-06-10 Aðferð til að búa til sildenafíl

Country Status (48)

Country Link
US (2) US5955611A (is)
EP (2) EP0916675B1 (is)
JP (2) JP2866841B2 (is)
KR (1) KR100207352B1 (is)
CN (2) CN1106399C (is)
AP (1) AP717A (is)
AR (1) AR003401A1 (is)
AT (2) ATE182150T1 (is)
AU (1) AU697684B2 (is)
BG (1) BG62554B1 (is)
BR (1) BR9703580A (is)
CA (1) CA2207694C (is)
CO (1) CO4780028A1 (is)
CZ (1) CZ290942B6 (is)
DE (2) DE69700321T2 (is)
DK (2) DK0916675T3 (is)
DZ (1) DZ2247A1 (is)
EA (1) EA000102B1 (is)
EG (1) EG24123A (is)
ES (2) ES2201397T3 (is)
GB (1) GB9612514D0 (is)
GR (1) GR3031087T3 (is)
HK (1) HK1033459A1 (is)
HN (1) HN1997000072A (is)
HR (1) HRP970326B1 (is)
HU (1) HU224497B1 (is)
ID (1) ID18745A (is)
IL (3) IL125411A (is)
IN (5) IN187350B (is)
IS (2) IS1922B (is)
MA (1) MA24205A1 (is)
MX (1) MX9704433A (is)
NO (2) NO304551B1 (is)
NZ (1) NZ328084A (is)
OA (1) OA10426A (is)
PE (2) PE1299A1 (is)
PL (1) PL189333B1 (is)
PT (1) PT916675E (is)
RS (2) RS49653B (is)
SA (1) SA97180124B1 (is)
SG (1) SG50024A1 (is)
SI (2) SI0812845T1 (is)
SK (5) SK283896B6 (is)
TN (1) TNSN97102A1 (is)
TR (1) TR199700470A2 (is)
UA (1) UA27085C2 (is)
UY (2) UY24585A1 (is)
ZA (1) ZA975259B (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
WO1998049166A1 (en) 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 勃起机能障碍治疗剂
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EP1049695B1 (de) 1997-11-12 2002-02-13 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
ATE247117T1 (de) 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
WO2000014088A1 (en) * 1998-09-04 2000-03-16 Ortho-Mcneil Pharmaceutical, Inc. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
SK4562002A3 (en) 1999-10-11 2003-04-01 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB0015462D0 (en) * 2000-06-22 2000-08-16 Pfizer Ltd Novel process for the preparation of pyrazolopyrimidinones
KR100525699B1 (ko) * 2000-06-22 2005-11-03 화이자 인코포레이티드 피라졸로피리미디논의 신규 제조 방법
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
EP1176142A1 (en) * 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
YU51701A (sh) * 2000-07-28 2003-12-31 Pfizer Inc. Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
JP4450365B2 (ja) * 2001-08-28 2010-04-14 シェーリング コーポレイション 多環式グアニンホスホジエステラーゼv阻害剤
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP1779852A3 (en) * 2004-01-05 2007-05-09 Teva Pharmaceutical Industries Ltd. Processes for the production of sildenafil base and citrate salt
JP2007517803A (ja) 2004-01-05 2007-07-05 テバ ファーマシューティカル インダストリーズ リミティド シルデナフィル塩基とクエン酸塩の製造方法
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US8071765B2 (en) * 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EP2374460A4 (en) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
CN102993205B (zh) * 2012-12-27 2015-04-15 华润赛科药业有限责任公司 一种高收率制备高纯度西地那非游离碱的纯化方法
CN103044330B (zh) * 2013-01-14 2018-11-13 常州亚邦制药有限公司 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺
CN105085526B (zh) * 2014-05-15 2017-08-01 重庆圣华曦药业股份有限公司 一种改进的西地那非制备方法
CN105753870B (zh) * 2016-04-01 2018-05-22 重庆康刻尔制药有限公司 一种西地那非杂质f及其制备方法和应用
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105837578A (zh) * 2016-04-05 2016-08-10 重庆康刻尔制药有限公司 一种西地那非杂质d的合成方法
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN112961160A (zh) * 2021-03-05 2021-06-15 遂成药业股份有限公司 一种西地那非的改良合成工艺
CN113754612B (zh) * 2021-10-26 2023-09-26 山东安舜制药有限公司 一种西地那非中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) * 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
RS49924B (sr) 2008-09-29
PT916675E (pt) 2003-11-28
MX9704433A (es) 1998-11-30
SK283896B6 (sk) 2004-04-06
DK0916675T3 (da) 2003-10-27
EP0916675A3 (en) 1999-07-14
SA97180124B1 (ar) 2006-02-08
KR100207352B1 (en) 1999-07-15
SK283895B6 (sk) 2004-04-06
CN1282740A (zh) 2001-02-07
CA2207694A1 (en) 1997-12-14
NZ328084A (en) 1998-08-26
DE69700321D1 (de) 1999-08-19
ATE246194T1 (de) 2003-08-15
SI0812845T1 (en) 1999-12-31
JP2866841B2 (ja) 1999-03-08
NO972481D0 (no) 1997-05-30
IN187320B (is) 2002-03-23
PE1299A1 (es) 1999-01-13
ES2201397T3 (es) 2004-03-16
JPH1081688A (ja) 1998-03-31
EA000102B1 (ru) 1998-08-27
JPH11171879A (ja) 1999-06-29
AR003401A1 (es) 1998-08-05
SK283894B6 (sk) 2004-04-06
UY24585A1 (es) 1997-12-02
DE69723846T2 (de) 2004-03-04
ID18745A (id) 1998-05-07
NO304551B1 (no) 1999-01-11
DZ2247A1 (fr) 2002-12-18
CO4780028A1 (es) 1999-05-26
ES2134051T3 (es) 1999-09-16
IN187318B (is) 2002-03-23
KR980002051A (ko) 1998-03-30
DK0812845T3 (da) 1999-11-29
IL125411A0 (en) 1999-03-12
OA10426A (en) 2001-12-07
YU25497A (sh) 1998-12-23
PL189333B1 (pl) 2005-07-29
SA97180124A (ar) 2005-12-03
US6066735A (en) 2000-05-23
IL121000A0 (en) 1997-11-20
CZ290942B6 (cs) 2002-11-13
SK74397A3 (en) 1998-06-03
SK283893B6 (sk) 2004-04-06
CN1106399C (zh) 2003-04-23
TR199700470A2 (xx) 1998-01-21
HUP9701048A2 (hu) 1998-12-28
BG62554B1 (bg) 2000-02-29
EP0812845B1 (en) 1999-07-14
UA27085C2 (uk) 2000-02-28
AP9701009A0 (en) 1997-07-31
IN187317B (is) 2002-03-23
IL121000A (en) 2000-02-29
IN187350B (is) 2002-03-30
US5955611A (en) 1999-09-21
HRP970326B1 (en) 2000-10-31
GR3031087T3 (en) 1999-12-31
BR9703580A (pt) 1998-11-10
EP0916675B1 (en) 2003-07-30
HU9701048D0 (en) 1997-08-28
CZ181197A3 (cs) 1998-03-18
NO985064D0 (no) 1998-10-30
ZA975259B (en) 1997-12-15
BG101569A (en) 1998-01-30
HRP970326A2 (en) 1998-06-30
MA24205A1 (fr) 1997-12-31
CN1168376A (zh) 1997-12-24
NO306115B1 (no) 1999-09-20
HK1033459A1 (en) 2001-08-31
DE69723846D1 (de) 2003-09-04
EP0812845A1 (en) 1997-12-17
SK283897B6 (sk) 2004-04-06
RS49653B (sr) 2007-09-21
SI0916675T1 (en) 2003-12-31
DE69700321T2 (de) 1999-11-04
CN1149206C (zh) 2004-05-12
PE20011303A1 (es) 2001-12-25
ATE182150T1 (de) 1999-07-15
HU224497B1 (hu) 2005-10-28
NO972481L (no) 1997-12-15
CA2207694C (en) 1999-11-23
HN1997000072A (es) 1997-12-26
HUP9701048A3 (en) 2000-10-30
IS1923B (is) 2004-03-15
UY24612A1 (es) 2000-09-29
NO985064L (no) 1997-12-15
EA199700061A1 (ru) 1997-12-30
GB9612514D0 (en) 1996-08-14
JP3058863B2 (ja) 2000-07-04
IL125411A (en) 2000-02-29
SG50024A1 (en) 1998-06-15
EG24123A (en) 2008-07-06
IS4503A (is) 1997-12-15
IS1922B (is) 2004-03-15
EP0916675A2 (en) 1999-05-19
AU2487897A (en) 1997-12-18
AU697684B2 (en) 1998-10-15
RS20060484A (en) 2007-04-10
AP717A (en) 1999-01-04
PL320555A1 (en) 1997-12-22
TNSN97102A1 (fr) 2005-03-15
IN187319B (is) 2002-03-23

Similar Documents

Publication Publication Date Title
IS1923B (is) Aðferð til að búa til sildenafíl
DK1226906T4 (da) Skaft til barberapparat
DK1614829T3 (da) Fremgangsmåde til fremstilling af hårde gulvplader
IS8368A (is) Ný aðferð
FI102426B1 (fi) Menetelmä muistin toteuttamiseksi
FI102424B1 (fi) Menetelmä muistin toteuttamiseksi
DE69727395D1 (de) Verfahren zur olefinisomerisierung
FI102425B1 (fi) Menetelmä muistin toteuttamiseksi
KR970001365A (ko) 알킬하이드로겐클로로실란의 제조방법
FR2751106B1 (fr) Methode de planification de transactions distribuees
NO965066D0 (no) Forseglingsmetode
IS5106A (is) Ný aðferð
DE69708229T2 (de) Muster-Herstellungsverfahren
DK0749677T3 (da) Fremgangsmåde til fremskaffelse af data
ID16815A (id) Metoda untuk menghasilkan tuangan
IT1290673B1 (it) Metodo di controllo di sigarette.
FI97961B (fi) Menetelmä puristepuun valmistamiseksi
EE200000540A (et) Tetrapeptiidi valmistamise meetod
IT1285910B1 (it) Metodo di gommatura
ID17503A (id) Metoda konstruksi
LV10943A (lv) N-benziloksikarbonilarginina 4-metilkumaril-7-amida iegusanas metode
ID16281A (id) Metode
FI981251A0 (fi) Menetelmä iso-tiosynnaattien valmistamiseksi
NO963693D0 (no) System for komplettering av brönner
SE9600725D0 (sv) Manufacturing method